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1  | INTRODUC TION
In recent years, there is an increasing interest in food protein-de-
rived peptides for their diverse physiological activities such as 
antioxidant, angiotensin-I-converting enzyme (ACE) inhibitory, 
and dipeptidyl peptidase-IV (DPP-IV) inhibitory activities. Many 
studies have been focused on the use of food protein as raw ma-
terials for the production of bioactive peptides (Ghribi et al., 2015; 
Nongonierma, Lalmahomed, Paolella, & FitzGerald, 2017; Uraipong 
& Zhao, 2018; Venuste et al., 2013). Among researches that have 
been made, the digestion of protein is the limiting factor in the 
release of bioactive peptides, with the most common and effective 
method to be enzymatic hydrolysis. The conventional method in 
the discovery of novel bioactive peptides includes not only en-
zymolysis in vitro or in vivo, but also a complex series of subse-
quent steps, that is, separation, purification, and identification of 
peptides with given bioactivity. With the development of bioin-
formatics, in silico analysis has been greatly used to investigate 
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Abstract
Quinoa protein has been paid more and more attention because of its nutritional 
properties and beneficial effects. With the development of bioinformatics, bioactive 
peptide database and computer-assisted simulation provide an efficient and time-
saving method for the theoretical estimation of potential bioactivities of protein. 
Therefore, the potential of quinoa protein sequences for releasing bioactive peptides 
was evaluated using the BIOPEP database, which revealed that quinoa protein, espe-
cially globulin, is a potential source of peptides with dipeptidyl peptidase-IV (DPP-IV) 
and angiotensin-I-converting enzyme (ACE) inhibitory activities. Three plant pro-
teases, namely papain, ficin, and stem bromelain, were employed for the in silico pro-
teolysis of quinoa protein. Furthermore, four tripeptides (MAF, NMF, HPF, and MCG) 
were screened as novel promising bioactive peptides by PeptideRanker. The bioac-
tivities of selected peptides were confirmed using chemical synthesis and in vitro 
assay. The present work suggests that quinoa protein can serve as a good source 
of bioactive peptides, and in silico approach can provide theoretical assistance for 
investigation and production of functional peptides.
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the bioactive features of protein and peptides, which is more 
economical and time-saving than conventional method. BIOPEP 
database, providing collection of sequences (proteins, bioactive 
peptides, allergenic proteins, and sensory peptides), can be used 
to predict biological activities about a protein sequence, and to es-
timate the release of bioactive peptides by proteolysis simulation 
using certain proteases (Minkiewicz, Dziuba, Iwaniak, Dziuba, & 
Darewicz, 2008). This in silico tools has been successfully applied 
in the investigation of bioactive peptides from different sources, 
including animal products, plant products, and seafood products, 
such as bovine meat proteins (Minkiewicz, Dziuba, & Michalska, 
2011), porcine myofibrillar proteins (Kęska & Stadnik, 2016), yak 
milk casein (Lin et al., 2018), cereal storage proteins (Cavazos & de 
Mejia, 2013), oilseed proteins (Han, Maycock, Murray, & Boesch, 
2019), giant grouper roe proteins (Panjaitan, Gomez, & Chang, 
2018), and portuguese oyster proteins (Gomez, Peralta, Tejano, & 
Chang, 2019). In addition, online tool PeptideRanker has the func-
tion of predicting the potential bioactive index of peptides, and 
ToxinPred has been developed to predict the toxicity of peptides.
Quinoa (Chenopodium quinoa Willd.) is an ancient crop and has 
been recognized as a potent food candidate due to its exceptional 
nutritive value. There is now much interest in quinoa protein for 
its good balance of amino acids, gluten-free property, and high di-
gestibility (Filho et al., 2017; Graf et al., 2015). In addition to the 
nutritional value, quinoa protein has been documented to exert 
some beneficial effects as a source of bioactive peptides, like ACE 
inhibition (Aluko & Monu, 2003), antioxidant (Aluko & Monu, 2003; 
Nongonierma, Maux, Dubrulle, Barre, & FitzGerald, 2015), DPP-IV 
inhibition (Nongonierma et al., 2015), antidiabetic (Vilcacundo, 
Martínez-Villaluenga, & Hernández-Ledesma, 2017), and colon can-
cer cell viability inhibitory effect (Vilcacundo, Miralles, Carrillo, & 
Hernández-Ledesma, 2018).
However, the potential of quinoa protein to release biological 
peptides has not been studied systematically. The aim of the present 
work was to study the potential use of quinoa protein as the precur-
sor of bioactive peptides based on in silico analysis, and to assess the 
potential of some enzymes to release bioactive peptides by enzy-
matic hydrolysis simulation. Furthermore, this in silico analysis was 
used for the exploration of novel bioactive peptides derived from 
quinoa protein.
2  | MATERIAL S AND METHODS
2.1 | Protein sequences and enzymes
Five sequences of quinoa seed storage proteins were selected for 
the in silico analysis: 2S albumin-like (XP_021758596), 11S seed 
storage globulin (AAS67036), 11S globulin seed storage protein 
2-like (XP_021770184), 13S globulin seed storage protein 1-like 
(XP_021752233), and 13S globulin seed storage protein 2-like 
(XP_021752668). Besides, soybean proteins, glycinin (P04347), 
β-conglycinin α′ (P11827), and β-conglycinin α (P0DO16), were 
taken as comparison sequences to assay the potential biological 
activity of different proteins. All sequence information was re-
trieved from NCBI (https ://www.ncbi.nlm.nih.gov/) and listed in 
Table 1.
In this study, three plant proteases were used for in silico pro-
teolysis: papain (EC 3.4.22.2), ficin (EC 3.4.22.3), and stem bro-
melain (EC 3.4.22.32). Meanwhile, pepsin (pH > 2.0, EC 3.4.23.1), 
trypsin (EC 3.4.21.4), and chymotrypsin (EC 3.4.21.1) were em-
ployed to evaluate the stability of the peptides against gastroin-
testinal digestion.
2.2 | Evaluation of quinoa proteins as a precursor of 
bioactive peptides via the BIOPEP database
Profiles for quinoa proteins as the precursor of bioactive peptides is 
available in the BIOPEP (http://www.uwm.edu.pl/bioch emia/index.
php/pl/biopep) using the “Profiles of potential biological activity” 
tool, shown as the type and location of bioactive fragment in a pro-
tein sequence. Meanwhile, the frequency of the occurrence of pep-
tides with given activity (A) in a protein was taken as the evaluation 
parameter and calculated based on the equation:
(1)A=a∕N
Source Protein Accession (NCBI) Length Abbreviation
Quinoa 2S albumin-like XP_021758596 142 2S
11S seed storage 
globulin
AAS67036 480 11S-1
11S globulin seed 
storage protein 2-like
XP_021770184 474 11S-2
13S globulin seed 
storage protein 1-like
XP_021752233 463 13S-1
13S globulin seed 
storage protein 2-like
XP_021752668 542 13S-2
Soybean Glycinin P04347 516 –
β-conglycinin α′ P11827 621 –
β-conglycinin α P0DO16 605 –
TA B L E  1   Quinoa and soybean protein 
sequences used for in silico analysis in this 
study
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where a is the number of peptides with given activity in the protein 
sequence, and N is the number of amino acid residues in the protein. 
The total frequency of occurrence of all bioactive peptides (∑A) in the 
protein was also calculated.
2.3 | In silico proteolysis and virtual screening
The proteolysis simulation provided by BIOPEP was adopted. 
Papain, ficin, and stem bromelain were independently applied to 
the protein sequences to release peptides. The frequency of re-
lease of peptides with given bioactivity by selected enzymes (AE) 
and the relative frequency of release of peptides with given ac-
tivity by selected enzymes (W) were calculated according to the 
equations:
where d is the number of peptides with given activity released from the 
protein sequence by selected enzyme, and N is the number of amino 
acid residues in the protein.
Then, the peptides with three amino acids were submitted to 
PeptideRanker (http://disti lldeep.ucd.ie/Pepti deRan ker/) for the 
calculation of theoretical bioactivity of peptides, and the results 
were presented as score values from 0 (poorest bioactivity) to 1 
(best bioactivity). Peptides with relatively high PeptideRanker score 
and no previously described bioactivity based on the information 
recorded in BIOPEP database were evaluated for their stability 
against the gastrointestinal digestion using BIOPEP simulation, and 
their toxicity using ToxinPred (http://crdd.osdd.net/ragha va/toxin 
pred/multi_submit.php). The solubility of the peptide was evaluated 
by the online Innovagen server, available at http://www.innov agen.
com/prote omics-tools .
2.4 | Peptide synthesis
Screened peptides were synthesized by the Sangon Biotech 
Company for the evaluation of in vitro DPP-IV and ACE inhibitory 
activities. The purity of the peptide was 99% verified by HPLC.
2.5 | Assay of DPP-IV inhibitory activity
The DPP-IV inhibition assay was determined using DPP-IV inhibi-
tor screening assay kit (KA1311, Abnova). Briefly, peptide sam-
ples (10 μl), dispersed in assay buffer (20 mM Tris-HCl containing 
100 mM NaCl and 1 mM EDTA, pH 8.0) at various concentrations, 
were mixed with assay buffer and DPP-IV in a 96-well plate. Then, 
substrate solution (Gly-Pro-Aminomethylcoumarin) was added to 
initiate the reactions. The mixture was incubated at 37°C for 30 min, 
and the fluorescence was measured using a plate reader (Synergy 
MX, Bio Tek) at an excitation wavelength of 350 nm and an emission 
wavelength of 450 nm. The concentration of the DPP-IV inhibitor 
required to inhibit 50% of DPP-IV activity under the above assay 
conditions was defined as the IC50, which was the mean value from 
three independent replicate assays.
2.6 | Assay of ACE inhibitory activity
The ACE inhibition assay was carried out with the ACE inhibitory 
assay kit (ACE kit-WST). Absorbance at 450 nm was measured using 
a plate reader (SpectraMax plus, Molecular devices), and the IC50 
value reported for each sample was the mean value from three inde-
pendent replicate assays.
2.7 | Statistical analysis
All tests for peptides bioactivities were conducted with three rep-
licates, and their data were expressed as the mean ± standard de-
viations. Statistical analysis was performed using SPSS version 16.0. 
Differences between the means were tested using one-way ANOVA 
with Duncan's test. Mean values were considered significantly dif-
ferent at p < .01.
3  | RESULTS AND DISCUSSIONS
3.1 | The potential of quinoa seed storage protein as 
a precursor of bioactive peptides
Globulin and albumin were found to be dominant in quinoa seed 
protein (Brinegar, Sine, & Nwokocha, 1996; Prakash & Pal, 1998). To 
investigate the potential of quinoa protein as precursors of bioac-
tive peptides, a total of five quinoa protein sequences with a range 
of 142–542 amino acids (Table 1 and Appendix S1) were selected 
and assessed by “Profiles of potential biological activity” of BIOPEP, 
and three soybean protein sequences as comparison. Soybean is an 
important crop in many countries for its high-quality protein and 
kinds of biological activities. Glycinin and β-conglycinin have been 
regarded as the good precursors of bioactive peptides (Han et al., 
2019; Singha, Vij, & Hati, 2014).
Based on the present limited information in BIOPEP database 
(as of 11 June 2019, 3,792 peptides functioned in 51 bioactivities 
have been collected in BIOPEP), fragments with 18 known bio-
logical activities were found in quinoa proteins (Figure 1). Among 
them, fragments with ACE inhibition, activating ubiquitin-mediated 
proteolysis, antiamnestic, antioxidative, DPP-IV inhibition, renin 
inhibition, inhibiting calmodulin-dependent phosphodiesterase 
(CaMPDE), and stimulating glucose uptake activities existed in all 
analyzed quinoa protein sequences.
(2)AE=d∕N
(3)W=AE∕A
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As for the total frequency of bioactive peptides occurrence, 
11S-2 (∑A = 1.2508) had the highest value of seven analyzed pro-
teins, followed by 11S-1 (∑A = 1.2480) and 13S-1 (∑A = 1.2443). 
These three quinoa proteins showed higher total frequency of bio-
active peptides occurrence than soybean proteins (Table 2). Quinoa 
albumin 2S had the weakest potential to act as precursor of bioac-
tive peptides, with the least bioactivities and lowest occurrence fre-
quency of bioactive peptides (∑A = 1.0139). Globulin is the principal 
precursor of bioactive peptides in quinoa seed.
DPP-IV (A(DPP-IV inhibitor) = 0.5211–0.6609) and ACE inhibitor 
(A(ACE inhibitor) = 0.3451–0.4208) were the major part of bioactive 
fragments in all selected protein sequences and were taken as the 
research focus in this paper. DPP-IV is a ubiquitous protease as-
sociated with the degradation of incretin and regulation of blood 
glucose levels, and drug based on the inhibition of its activity is 
one of the most recent treatments for type 2 diabetes mellitus 
(Juillerat-Jeanneret, 2014). Food protein-derived DPP-IV inhibitors 
have been intensively studied over the last few decades (Lacroix 
& Li-Chan, 2012). ACE plays a significant role in blood pressure 
regulation by promoting the production of the active hyperten-
sive hormone and inactivation of vasodilator peptide, making it 
one of the promising physiological targets for antihypertensive 
drugs (Miralles, Amigo, & Recio, 2018; Udenigwe & Mohan, 2014). 
Various dietary proteins have been employed for the generation 
of ACE inhibitory hydrolysates, including animal products, marine 
organisms, and plants (Lee & Hur, 2017).
The highest release frequency of DPP-IV and ACE inhibitor was 
found in quinoa 13S-1 and 11S-1, respectively. Quinoa globulin 11S-
1, 11S-2, and 13S-1 exerted higher release frequency for DPP-IV and 
ACE inhibitory peptides than analyzed soybean proteins. Frequency 
parameters of 13S-2 were slightly lower than the highest value in soy-
bean proteins. Our study demonstrated that globulin in quinoa seed 
presented a high potential as a precursor for the production of various 
biologically active peptides, especially DPP-IV and ACE inhibitors.
3.2 | In silico proteolysis of quinoa proteins
Bioactive peptides encrypted within the natural food protein are 
supposed to be released by enzymolysis to exert their biological 
function. A number of food processing enzymes were previously 
used for the generation of bioactive peptides from a variety of 
natural sources (Fu, Wu, Zhu, & Xiao, 2016; Lin, Zhang, Han, Meng, 
et al., 2018). In our study, three commercial plant proteases pa-
pain, ficin, and stem bromelain were applied, respectively, to the 
F I G U R E  1   The frequency of the occurrence of peptides with 
given activity in quinoa protein performed by BIOPEP. (1. ACE 
inhibitor; 2. Peptide activating ubiquitin-mediated proteolysis; 3. 
α-glucosidase inhibitor; 4. Antiamnestic peptide; 5. Anticancer 
peptide; 6. Antioxidative peptide; 7. Calcium-binding peptide; 8. 
Antithrombotic peptide; 9. Bacterial permease ligand; 10. DPP-IV 
inhibitor; 11. Embryotoxic; 12. Hydroxy methylglutaryl coenzyme 
A reductase inhibitor; 13. Renin inhibitor; 14. Immunomodulating 
peptide; 15. CaMPDE inhibitor; 16. Neuropeptide; 17. Peptide 






(DPP-IV inhibitor) (ACE inhibitor)
Quinoa 2S 9 1.0139 0.5211 0.3451
11S-1 14 1.2480 0.6354 0.4208
11S-2 13 1.2508 0.6540 0.3945
13S-1 15 1.2443 0.6609 0.4168
13S-2 13 1.2082 0.6181 0.3930
Soybean Glycinin 13 1.1628 0.6182 0.3876
β-conglycinin α′ 15 1.1949 0.5781 0.3833
β-conglycinin α 15 1.2100 0.5752 0.3934
TA B L E  2   The frequency of occurrence 
of peptides with a given activity (A) in 
selected protein sequences
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selected quinoa protein sequences by “Enzyme(s) action” of BIOPEP 
(Appendix S2). Hydrolysates with the degree of hydrolysis (DH) be-
tween 31.2925% and 52.1298% were obtained by in silico proteoly-
sis (Table 3). Among the three enzymes, stem bromelain gave the 
highest DHs for five quinoa proteins, while the release of bioactive 
peptides is not proportional to the DH of hydrolysate.
The evaluation parameters (AE and W) of DPP-IV and ACE inhib-
itory peptides generated in this study were shown in Table 3. The 
release frequency (AE) of DPP-IV inhibitory peptides was higher than 
that of ACE inhibitory peptides generated from the same sequence 
by the same enzyme, and the similar results were seen in the relative 
release frequency (W) of peptides except 11S-2 and 13S-1 treated 
by ficin and stem bromelain.
Different enzymes have different potential to release bioactive 
peptides from proteins, which attribute to their specific cleavage sites 
(Gomez et al., 2019). For example, Fu et al. (2016) performed in silico 
proteolysis of bovine collagen by twenty-seven different enzymes and 
found that papain was the most effective protease to release ACE in-
hibitory peptides theoretically. In our study, papain-treated quinoa pro-
teins (except 11S-1) exerted relatively higher release frequency index 
of DPP-IV inhibitors than the other two enzymes. Similarly, papain has 
relative strong potential as an enzyme releasing ACE inhibitory pep-
tides from quinoa proteins (except 11S-2). This might be because pa-
pain shared most of the cutting sites with two other enzymes, except 
for those from the N-terminus (Appendix S3).
The sequences of identified DPP-IV and ACE inhibitory pep-
tides predicted to be released from quinoa proteins by in silico 
enzymolysis were presented in Table 4. These bioactive peptides 
are made up of relatively few amino acids; exactly, most of them 
are dipeptides, except for IVR, IVY, AQL, VTR, and NKL. Actually, 
there were still plenty of peptides with no previously described 
bioactivity released from in silico enzymolysis of quinoa proteins. 
As for the bioactivity of the unknown peptides, further study is 
required.
3.3 | Virtual screening of novel bioactive peptides
Herein, tripeptides released from in silico enzymolysis of quinoa pro-
teins were further analyzed for the discovery of novel bioactive pep-
tides with specific effect. Analysis of PeptideRanker predicted the 
theoretical bioactivity of peptides with the score values from 0.0222 
to 0.9816 (Appendix S4). The top five peptides with high score were 
WCY, MAF, NMF, HPF, and MCG. Among them, WCY has been found 
in oat protein as an ACE inhibitory peptide (Bleakley, Hayes, O’ Shea, 
Gallagher, & Lafarga, 2017). However, the other four peptides, with 
no previously described bioactivity based on BIOPEP database and 
literatures, were subjected to in silico prediction of toxicity, solubil-
ity, and stability against the gastrointestinal digestion.
As shown in Table 5, the prediction has been given that all the 
selected peptides are nontoxic, and expected to be poorly soluble 
in water due to their high hydrophobic residues. To exert physi-
ology effect, it is necessary that peptides survive gastrointestinal 
digestion. However, these four peptides exerted undesired low 
stability in simulative gastrointestinal digestion. As Udenigwe and 
Fogliano (2017) reported, encapsulation techniques need to be de-
veloped in the preparation of bioactive peptides in order to protect 
peptides from undesired degradation. It is also notable that two pep-
tides were partly hydrolyzed, accompanying with the new genera-
tion of dipeptides PF and CG. PF is a DPP-IV inhibitor documented 
in BIOPEP database, and CG has high theoretical bioactivity (0.9319) 
predicted by PeptideRanker. It indicated that these peptides could 
act as not only bioactive substance but also promising precursor.
3.4 | In vitro assessment of biological activity
In order to verify the bioactive effect of selected peptides, four 
chemically synthesized peptides were subjected to in vitro as-
sessment of DPP-IV and ACE inhibition activity. The assay results 
showed that all the peptides exhibited the positive ability in in-
hibiting DPP-IV and ACE activity (Table 6). HPF exerted strongest 
DPP-IV inhibition activity with IC50 value of 13.69 μg/ml, followed 
by MCG (45.95 μg/ml). MCG was the most potent ACE inhibitor 
with IC50 value of 6.48 μg/ml, followed by HPF (40.08 μg/ml). The 
inhibitory activity on DPP-IV and ACE of MAF and NMF was com-
paratively lower despite the higher PeptideRanker score, which in-
dicated that they may play a role in other biological functions.
Nongonierma et al. (2015) reported that quinoa protein hydroly-
sate produced by papain has in vitro DPP-IV inhibitory effect, while 
the peptide sequences have not been identified. Peptide IQAEGGLT, 
released from quinoa protein by pepsin-pancreatin sequential diges-
tion, has been reported to exert DPP-IV inhibitory activity with an 
IC50 value of 267.81 μM (Vilcacundo et al., 2017). Compared with 
the bioactive peptides released by in silico proteolysis in this study, 
it is confirmed that the outcomes of in silico proteolysis and ex-
perimental enzymolysis were not an exact match (Nongonierma & 
FitzGerald, 2017; Tu, Cheng, Lu, & Du, 2018). In silico approach pro-
vides an alternative strategy for the investigation of novel bioactive 
peptides, but also has its limitations. Previous results showed that 
the products of enzymatic hydrolysis changed with the degree of 
hydrolysis, which was affected by kinds of factors, such as protein 
structural features, enzymatic activity, temperature, pH, hydroly-
sis time, and enzyme–substrate ratios (Fu et al., 2016; Han et al., 
2019; Tu et al., 2018). However, the enzymolysis by in silico tools was 
rather idealistic, the digestion happened in every specific cutting site 
of enzymes, and it was carried out completely. Besides, in silico anal-
ysis was based on the current knowledge in BIOPEP database. The 
database is constantly updated, and the analysis results might be 
changed with new data.
4  | CONCLUSION
Based on the selected protein sequences, our study revealed that the 
quinoa proteins contain various biological active peptides, especially 
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DPP-IV and ACE inhibitors. In silico proteolysis showed that papain 
has relative strong potential as an enzyme releasing DPP-IV and 
ACE inhibitory peptides, although it exerts lower DH than stem bro-
melain. Furthermore, four novel bioactive tripeptides were selected 
by virtual screening and their bioactivities were confirmed using 
chemical synthesis and in vitro assay. In spite of some limitations in 
this in silico analysis, there is enough evidence to conclude that the 
quinoa protein is a promising precursor for production of bioactive 
peptides, and in silico proteolysis may serve the productive practice 
of the preparation of bioactive peptides.
Protein Enzymes DHt (%)
DPP-IV inhibitor ACE inhibitor
AE W AE W
2S Papain 35.3741 0.0541 0.1082 0.0270 0.0833
Ficin 31.2925 0.0270 0.0540 0.0135 0.0416
Stem bromelain 35.3741 0.0541 0.1082 0.0203 0.0626
11S-1 Papain 43.6105 0.0850 0.1386 0.0506 0.1244
Ficin 44.0162 0.0668 0.1089 0.0364 0.0895
Stem bromelain 52.1298 0.0972 0.1585 0.0425 0.1044
11S-2 Papain 39.0593 0.0735 0.1177 0.0408 0.1087
Ficin 44.1718 0.0735 0.1177 0.0510 0.1358
Stem bromelain 50.3067 0.0633 0.1014 0.0408 0.1087
13S-1 Papain 42.0168 0.1027 0.1622 0.0566 0.1429
Ficin 40.7563 0.0566 0.0894 0.0398 0.1005
Stem bromelain 51.6807 0.0692 0.1093 0.0482 0.1217
13S-2 Papain 40.0359 0.0663 0.1121 0.0376 0.0999
Ficin 46.6786 0.0591 0.0999 0.0358 0.0951
Stem bromelain 52.0646 0.0573 0.0969 0.0323 0.0858
TA B L E  3   The parameters describing 
the predicted efficiency of release of 
bioactive fragments from quinoa protein 
by in silico enzymolysis
TA B L E  4   BIOPEP analysis of bioactive peptides predicted to be released from quinoa protein based on in silico enzymolysis with papain, 
ficin, and stem bromelain
 DPP-IV inhibitors ACE inhibitors
Papain 171a: 96:
 VV (1)b, SP (1), KP (1), NP (2), QP (1), HL (2), AL (11), SL (4), VR (2), 
PL (3), WI (1), YT (1), AD (2), AE (4), AF (5), AG (19), AH (1), AT (1), 
AY (1), DP (1), EG (3), EH (1), ES (1), ET (1), HR (2), HT (1), IH (1), IL (3), 
IR (2), KF (2), KG (1), KR (1), KT (4), MR (4), NF (1), NG (5), NL (1), 
NR (1), PF (1), PG (1), QD (1), QF (4), QG (17), QH (3), QI (1), QL (17), 
QN (1), QT (6), QV (1), QW (1), SF (4), VF (4), VL (3), VT (3), YL (3), 
YR (1)
IR (2), IY (1), VF (4), PR (1), YL (3), AY (1), 
IVR (1), PL (3), AF (5), KR (1), IF (1), AG (19), 
HL (2), KG (1), HG (1), QG (17), SG (6), EG (3), 
NG (5), PG (1), VR (2), NF (1), SF (4), KF (2), 
AR (3), KP (1), IE (1), AH (1), IL (3)
Ficin 132: 83:
EK (1), AL (2), VR (4), PL (5), WR (1), AG (9), EG (4), EH (1), ES (6), EY (1), 
IH (1), IL (4), IR (3), MG (1), MK (2), MR (3), NF (1), NG (8), NH (1), 
NL (4), NR (1), NY (1), PF (3), PG (2), PH (1), PK (2), PS (8), QG (4), 
QH (2), QL (8), QS (4), QY (1), TG (1), TK (4), TL (1), TR (4), TS (4), 
VF (7), VG (1), VH (1), VK (1), VL (4), VS (4), VY (1)
IR (3), IY (2), VF (7), VY (1), PR (4), IVR (1), 
PL (5), IVY (1), VK (1), IF (2), VG (1), AG (9), 
MG (1), QG (4), TG (1), EG (4), NG (8), PG (2), 
VR (4), QK (6), NY (1), NF (1), NK (1), AR (2), 
EY (1), EK (1), PH (1), AQL (2), VTR (1), DY (1), 
IL (4)
Stem bromelain 149: 84:
MA (2), KA (2), PA (2), HA (1), IA (2), WV (1), HL (2), PL (6), WR (1), 
YT (2), EG (4), ES (6), ET (2), EV (5), HR (3), HS (2), HT (1), HV (3), 
IL (5), IR (9), KF (2), KG (1), KR (2), KS (2), KT (4), MR (5), MV (1), 
NA (5), NF (1), NG (8), NL (3), NR (1), NV (2), PF (2), PG (3), PS (9), 
PT (1), QA (2), QG (6), QL (8), QS (5), QT (1), QV (2), YF (1), YL (3), 
YR (2), YS (2), YV (4)
IR (9), PR (4), YL (3), PL (6), IA (2), KR (2), IF (1), 
IG (2), HL (2), KG (1), DA (3), HG (1), QG (6), 
EG (4), EA (6), NG (8), PG (3), NKL (1), NF (1), 
KF (2), KA (2), EV (5), PT (1), YV (4), IL (5)
aThe numbers in bold indicate the total number of sequences with given activity released from quinoa proteins by in silico enzymolysis. 
bThe numbers in the parentheses indicate the repetitions of the bioactive sequences. 
     |  1421GUO et al.
ACKNOWLEDG MENTS
This work was supported by the Hebei Provincial Key Research 
and Development Plan (Introduction and Quality Evaluation of 
Quinoa Germplasm, 19227527D-01), the Agricultural Science 
and Technology Innovation Program (Minor Grain Nutrition and 
Function) of CAAS, and the International Science and Technology 
Cooperation Programme of China (KY20142023).
CONFLIC TS OF INTERE S T
The authors declare that they have no conflicts of interest.
E THIC AL APPROVAL
There was no human or animal testing in this study.
ORCID
Huimin Guo  https://orcid.org/0000-0001-9581-4557 
Xiushi Yang  https://orcid.org/0000-0002-2438-5545 
Guixing Ren  https://orcid.org/0000-0002-1306-7349 
R E FE R E N C E S
Aluko, R. E., & Monu, E. (2003). Functional and bioactive properties 
of quinoa seed protein hydrolysates. Journal of Food Science, 68(4), 
1254–1258. https ://doi.org/10.1111/j.1365-2621.2003.tb096 35.x
Bleakley, S., Hayes, M., O’ Shea, N., Gallagher, E., & Lafarga, T. (2017). 
Predicted release and analysis of novel ACE-I, renin, and DPP-IV 
inhibitory peptides from common oat (Avena sativa) protein hy-
drolysates using in silico analysis. Foods, 6(12), 108. https ://doi.
org/10.3390/foods 6120108
Brinegar, C., Sine, B., & Nwokocha, L. (1996). High-cysteine 2S seed stor-
age proteins from quinoa (Chenopodium quinoa). Journal of Agricultural 
and Food Chemistry, 44(7), 1621–1623. https ://doi.org/10.1021/
jf950 830+
Cavazos, A., & de Mejia, E. G. (2013). Identification of bioactive peptides 
from cereal storage proteins and their potential role in prevention 
of chronic diseases. Comprehensive Reviews in Food Science and Food 
Safety, 12(4), 364–380. https ://doi.org/10.1111/1541-4337.12017 
Filho, A. M. M., Pirozi, M. R., Borges, J. T. D. S., Pinheiro Sant'Ana, H. M., 
Chaves, J. B. P., & Coimbra, J. S. D. R. (2017). Quinoa: Nutritional, 
functional, and antinutritional aspects. Critical Reviews in Food 
Science and Nutrition, 57, 1618–1630. https ://doi.org/10.1080/10408 
398.2014.1001811
Fu, Y., Wu, W., Zhu, M. P., & Xiao, Z. G. (2016). In silico assessment of 
the potential of patatin as a precursor of bioactive peptides. Journal 
of Food Biochemistry, 40, 366–370. https ://doi.org/10.1111/
jfbc.12213 
Fu, Y., Young, J. F., Lokke, M. M., Lametsch, R., Aluko, R. E., & Therkildsen, 
M. (2016). Revalorisation of bovine collagen as a potential precursor 
of angiotensin I-converting enzyme (ACE) inhibitory peptides based 
on in silico and in vitro protein digestions. Journal of Functional Foods, 
24, 196–206. https ://doi.org/10.1016/j.jff.2016.03.026
Ghribi, A. M., Sila, A., Przybylski, R., Nedjar-Arroume, N., Makhlouf, I., 
Blecker, C., … Besbes, S. (2015). Purification and identification of 
novel antioxidant peptides from enzymatic hydrolysate of chickpea 
(Cicer arietinum L.) protein concentrate. Journal of Functional Foods, 
12, 516–525. https ://doi.org/10.1016/j.jff.2014.12.011
Gomez, H. L. R., Peralta, J. P., Tejano, L. A., & Chang, Y. W. (2019). In silico 
and in vitro assessment of portuguese oyster (Crassostrea angulata) 
proteins as precursor of bioactive peptides. International Journal of 
Molecular Sciences, 20, 5191. https ://doi.org/10.3390/ijms2 0205191
Graf, B. L., Rojas-Silva, P., Rojo, L. E., Delatorre-Herrera, J., Baldeón, M. 
E., & Raskin, I. (2015). Innovations in health value and functional food 
development of quinoa (Chenopodium quinoa Willd.). Comprehensive 
Reviews in Food Science and Food Safety, 14(4), 431–445. https ://doi.
org/10.1111/1541-4337.12135 
Han, R. X., Maycock, J., Murray, B. S., & Boesch, C. (2019). Identification 
of angiotensin converting enzyme and dipeptidyl peptidase-IV inhib-
itory peptides derived from oilseed proteins using two integrated 
bioinformatic approaches. Food Research International, 115, 283–291. 
https ://doi.org/10.1016/j.foodr es.2018.12.015
Juillerat-Jeanneret, L. (2014). Dipeptidyl peptidase IV and its inhibitors: 
Therapeutics for Type 2 diabetes and what else? Journal of Medicinal 
Chemistry, 57(6), 2197–2212. https ://doi.org/10.1021/jm400 658e
Kęska, P., & Stadnik, J. (2016). Porcine myofibrillar proteins as poten-
tial precursors of bioactive peptides – An in silico study. Food and 
Function, 7, 2878–2885. https ://doi.org/10.1039/C5FO0 1631B 
Lacroix, I. M. E., & Li-Chan, E. C. Y. (2012). Evaluation of the potential 
of dietary proteins as precursors of dipeptidyl peptidase (DPP) - IV 
inhibitors by an in silico approach. Journal of Functional Foods, 4(2), 
403–422. https ://doi.org/10.1016/j.jff.2012.01.008
Lee, S. Y., & Hur, S. J. (2017). Antihypertensive peptides from animal 
products, marine organisms, and plants. Food Chemistry, 228, 506–
517. https ://doi.org/10.1016/j.foodc hem.2017.02.039
Lin, K., Zhang, L. W., Han, X., Meng, Z. X., Zhang, J. M., Wu, Y. F., & 
Cheng, D. Y. (2018). Quantitative structure-activity relationship 
modeling coupled with molecular docking analysis in screening of 
angiotensin I-converting enzyme inhibitory peptides from Qula ca-
sein hydrolysates obtained by two-enzyme combination hydrolysis. 
TA B L E  5   Predicted results of PeptideRanker score, toxicity, solubility, and stability against the gastrointestinal digestion of selected 
peptides
Peptide Protein Location PeptideRanker score Toxicity Solubility Simulated Digestion
MAF 13S-1 f (1–3) 0.9676 Non-Toxin Poor M-A-F
NMF 11S-2 f (342–344) 0.9624 Non-Toxin Poor N-M-F
HPF 11S-2 f (97–99) 0.9502 Non-Toxin Poor H-PF
MCG 2S f (128–130) 0.9502 Non-Toxin Poor M-CG
TA B L E  6   IC50 values (μg/ml) of chemically synthesized peptides 
in DPP-IV and ACE inhibitory activities
Peptide DPP-IV inhibition ACE inhibition
MAF 124.35 ± 1.75a 55.93 ± 1.09b
NMF 52.26 ± 0.83b 62.34 ± 1.21a
HPF 13.69 ± 0.76d 40.08 ± 0.59c
MCG 45.95 ± 0.91c 6.48 ± 0.12d
Note: Mean values followed by different letters in a column are 
significantly different (p < .01).
1422  |     GUO et al.
Journal of Agricultural and Food Chemistry, 66, 3221–3228. https ://
doi.org/10.1021/acs.jafc.8b00313
Lin, K., Zhang, L. W., Han, X., Xin, L., Meng, Z. X., Gong, P. M., & Cheng, 
D. Y. (2018). Yak milk casein as potential precursor of angiotensin 
I-converting enzyme inhibitory peptides based on in silico proteol-
ysis. Food Chemistry, 254, 340–347. https ://doi.org/10.1016/j.foodc 
hem.2018.02.051
Minkiewicz, P., Dziuba, J., Iwaniak, A., Dziuba, M., & Darewicz, M. (2008). 
BIOPEP database and other programs for processing bioactive pep-
tide sequences. Journal of AOAC International, 91, 965–980. https ://
doi.org/10.1134/S1061 93480 8070216
Minkiewicz, P., Dziuba, J., & Michalska, J. (2011). Bovine meat proteins as 
potential precursors of biologically active peptides – A computational 
study based on the BIOPEP database. Food Science and Technology 
International, 17(1), 39–45. https ://doi.org/10.1177/10820 13210 
368461
Miralles, B., Amigo, L., & Recio, I. (2018). Critical review and perspectives 
on food derived antihypertensive peptides. Journal of Agricultural 
and Food Chemistry, 66, 9384–9390. https ://doi.org/10.1021/acs.
jafc.8b02603
Nongonierma, A. B., & FitzGerald, R. J. (2017). Strategies for the dis-
covery and identification of food protein-derived biologically active 
peptides. Trends in Food Science and Technology, 69, 289e305. https ://
doi.org/10.1016/j.tifs.2017.03.003
Nongonierma, A. B., Lalmahomed, M., Paolella, S., & FitzGerald, R. J. 
(2017). Milk protein isolate (MPI) as a source of dipeptidyl peptidase 
IV (DPP-IV) inhibitory peptides. Food Chemistry, 231, 202–211. https 
://doi.org/10.1016/j.foodc hem.2017.03.123
Nongonierma, A. B., Maux, S. L., Dubrulle, C., Barre, C., & FitzGerald, R. 
J. (2015). Quinoa (Chenopodium quinoa Willd.) protein hydrolysates 
with in vitro dipeptidyl peptidase IV (DPP-IV) inhibitory and antiox-
idant properties. Journal of Cereal Science, 65, 112–118. https ://doi.
org/10.1016/j.jcs.2015.07.004
Panjaitan, F. C. A., Gomez, H. Y. R., & Chang, Y. W. (2018). In silico analysis 
of bioactive peptides released from giant grouper (Epinephelus lance-
olatus) roe proteins identified by proteomics approach. Molecules, 23, 
2910. https ://doi.org/10.3390/molec ules2 3112910
Prakash, D., & Pal, M. (1998). Chenopodium: Seed protein, fractionation 
and amino acid composition. International Journal of Food Sciences 
and Nutrition, 49(4), 271–275. https ://doi.org/10.3109/09637 48980 
9089398
Singha, B. P., Vij, S., & Hati, S. (2014). Functional significance of bioactive 
peptides derived from soybean. Peptides, 54, 171–179. https ://doi.
org/10.1016/j.pepti des.2014.01.022
Tu, M. L., Cheng, S. Z., Lu, W. H., & Du, M. (2018). Advancement and 
prospects of bioinformatics analysis for studying bioactive peptides 
from food-derived protein: Sequence, structure, and functions. 
Trends in Analytical Chemistry, 105, 7–17. https ://doi.org/10.1016/j.
trac.2018.04.005
Udenigwe, C. C., & Fogliano, V. (2017). Food matrix interaction and 
bioavailability of bioactive peptides: Two faces of the same coin? 
Journal of Functional Foods, 35, 9–12. https ://doi.org/10.1016/j.
jff.2017.05.029
Udenigwe, C. C., & Mohan, A. (2014). Mechanisms of food pro-
tein-derived antihypertensive peptides other than ACE inhibition. 
Journal of Functional Foods, 8C, 45–52. https ://doi.org/10.1016/j.
jff.2014.03.002
Uraipong, C., & Zhao, J. (2018). In vitro digestion of rice bran proteins 
produces peptides with potent inhibitory effects on α-glucosidase 
and angiotensin I converting enzyme. Journal of the Science of Food 
and Agriculture, 98, 758–766. https ://doi.org/10.1002/jsfa.8523
Venuste, M., Zhang, X. M., Shoemaker, C. F., Karangwa, E., Abbas, S., 
& Kamdem, P. E. (2013). Influence of enzymatic hydrolysis and en-
zyme type on the nutritional and antioxidant properties of pump-
kin meal hydrolysates. Food and Function, 4, 811–820. https ://doi.
org/10.1039/c3fo3 0347k 
Vilcacundo, R., Martínez-Villaluenga, C., & Hernández-Ledesma, B. (2017). 
Release of dipeptidyl peptidase IV, α-amylase and α-glucosidase in-
hibitory peptides from quinoa (Chenopodium quinoa Willd.) during in 
vitro simulated gastrointestinal digestion. Journal of Functional Foods, 
35, 531–539. https ://doi.org/10.1016/j.jff.2017.06.024
Vilcacundo, R., Miralles, B., Carrillo, W., & Hernández-Ledesma, B. 
(2018). In vitro chemopreventive properties of peptides released 
from quinoa (Chenopodium quinoa Willd.) protein under simulated 
gastrointestinal digestion. Food Research International, 105, 403–411. 
https ://doi.org/10.1016/j.foodr es.2017.11.036
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.    
How to cite this article: Guo H, Richel A, Hao Y, et al. Novel 
dipeptidyl peptidase-IV and angiotensin-I-converting enzyme 
inhibitory peptides released from quinoa protein by in silico 
proteolysis. Food Sci Nutr. 2020;8:1415–1422. https ://doi.
org/10.1002/fsn3.1423
